Citigroup Rates Glaukos (GKOS) buy, $162 Price Target

Citigroup Maintains Buy Rating on GKOS

Citigroup has reiterated its buy rating on Glaukos Corporation (NYSE: GKOS), setting a price target of $162 on June 11, 2026. This comes as shares of Glaukos are currently trading at $124.22, which is considerably lower than the company's 52-week high of $191.62. This could indicate potential for growth in the stock as it recovers.

Analysts Set New Price Targets

Citigroup's latest rating reflects confidence in Glaukos' performance in the healthcare sector, specifically within medical devices. The firm believes that the company's innovative products, which include therapies for glaucoma and other eye conditions, position it well for future growth. The average price target among analysts stands at $197.75, with a range that goes as high as $225, suggesting a strong consensus on the company's potential.

Several other firms have also raised or maintained their ratings on GKOS in recent months. On October 12, 2026, BTIG maintained its buy rating with a target bump to $205. Jefferies also maintained a buy rating on September 22, 2026, now targeting $210, which indicates strong support for Glaukos from multiple analysts.

Current Stock Position

As Glaukos trades at $124.22, the stock is well below its 50-day moving average of $171.13. This suggests that the stock may be undervalued compared to its historical performance. The recent analyst ratings suggest a belief in the company's ability to rebound as the market recognizes its value. Investors may want to watch for any shifts in market sentiment.

Recent Earnings

Glaukos reported revenue of $612.8 million, representing a growth rate of approximately 49.5%. However, the company is currently unprofitable with an EPS of -$3.28 and a negative net margin of about 30.7%. The next earnings report is expected on October 28, 2026, and could provide further insights into the company’s financial health and strategy moving forward.

What GKOS Does

Glaukos Corporation focuses on developing innovative therapies for the treatment of eye diseases, including glaucoma. The company offers a range of products designed to enhance the natural outflow of fluid in the eye, which is crucial in managing conditions like glaucoma. Given the ongoing demand for effective treatments, Glaukos' market position appears promising.

What's Ahead for GKOS

Investors will be keenly awaiting Glaukos' next earnings due on October 28, 2026, which could influence future analyst ratings and stock performance. As a reminder, Citigroup's reaffirmation of its buy rating highlights the confidence in Glaukos’ potential despite current challenges. Keep an eye on future analyst updates as more information becomes available.